Una investigación revela una rara y fuerte tendencia a matar arañas de una especie por parte de arañas de otra, sin que haya aparentemente una explicación lógica para dicha conducta. Se diría que las arañas de la especie agresora detestan a las otras …
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD Vaginal Panel on the BD COR™ System.
At a meeting with analysts and investors at its Investor Day, members of the executive leadership team of Quest Diagnostics Incorporated, the world’s leading provider of diagnostic information services, will discuss the company’s priorities to grow revenues and create shareholder value.
Que el calentamiento global potenciará las sequías parece una predicción fácil. Predecir hasta qué punto propiciará inundaciones, sobre todo a escala regional, es más difícil. Una investigación reciente ha explorado esta última cu …
El robot ARTEMIS (Advanced Robotic Technology for Enhanced Mobility and Improved Stability), está listo para entrar en acción. Es el más avanzado de entre todos los de tipo humanoide que han sido creados en la Universidad de California en Los Ángeles (UCLA). &nb …
ARTEMIS, robot humanoide tan ágil como para jugar al fútbol Read More »
Evotec SE announced progress within the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.
OKYO Pharma Limited announced that its planned trial evaluating the efficacy and safety of OK-101 in subjects with DED has been posted on the ClinicalTrials.gov public website.
Anaveon announced the first patient dosed with ANV419 in the OMNIA-2 study – a Phase I/II study assessing the safety, tolerability and preliminary efficacy of ANV419 for the treatment of patients with relapsed / refractory multiple myeloma as monotherapy and in combination with daratumumab and hyaluronidase-fihj1, or with lenalidomide plus dexamethasone.
Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces its full-year 2022 financial results and provides a business update.
Sensorion Reports Full-Year 2022 Financial Results and Business Update Read More »
Biovica International DiviTum® TKa ready for clinical use in the US
